Rehabilitation medicine: 3. Management of adult spasticity

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 11, 2003, Pages 1173-1179

  Satkunam, Lalith E ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; BACLOFEN; BOTULINUM TOXIN A; CLONIDINE; DANTROLENE; DRONABINOL; GABAPENTIN; PHENOL; POTASSIUM CHANNEL BLOCKING AGENT; TIZANIDINE;

ADULT; ADULTHOOD; ATAXIA; BLOOD BRAIN BARRIER; BRADYCARDIA; CHRONIC DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; FATIGUE; FEVER; HALLUCINATION; HEALTH CARE COST; HUMAN; HYPOTENSION; INJECTION; LIVER TOXICITY; LOW DRUG DOSE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OCCUPATIONAL THERAPY; PAIN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHYSIOTHERAPY; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SPASTICITY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VERTIGO; WOUND INFECTION; XEROSTOMIA;

EID: 0345376189     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Medical Pubs; 1980. p. 487-9.
2. Young RR. Spasticity: a review. Neurology 1994;44(Suppl):S12-20.
3. Rymer W, Katz RT. Mechanisms of spastic hypertonia. In: Katz RT, editor. Spasticity: state of the art review. Vol. 8. Philadelphia: Hanley & Belfus; 1994. p. 441-54.
4. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67(2):206-7.
5. Tizard JP. Cerebral palsies: treatment and prevention. The Croonian lecture 1978. J R Coll Physicians Lond 1980;14(2):72-7,80.
6. Bohannon RW. Tilt table standing for reducing spasticity after spinal cord injury. Arch Phys Med Rehabil 1993;74(10):1121-2.
7. Weingarden HP, Zeilig G, Heruti R, Shemesh Y, Ohry A, Dar A, et al. Hybrid functional electrical stimulation orthosis system for the upper limb: effects on spasticity in chronic stable hemiplegia. Am J Phys Med Rehabil 1998;77(4):276-81.
8. Katz RT, Campagnolo DE. Pharmacologic management of spasticity. In: Katz RT, editor. Spasticity: state of the art review. Vol 8. Philadelphia: Hanley & Belfus; 1994. p. 473-80.
9. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments [review]. Muscle Nerve Suppl 1997;6:S92-120.
10. Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000;81(2):164-9.
11. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997;35(10):686-9.
12. United Kingdom Tizanidine Trial Group. A double-blind, placebo controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994;44(11 Suppl 9):S70-8.
13. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North America Tizanidine Study Group. Neurology 1994;44(11 Suppl 9):S44-51; discussion: S51-2.
14. Potter PJ, Hayes KC, Segal JL, Hsieh JT, Brunnemann SR, Delaney GA, et al. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998;15(10):837-49.
15. Petro DJ, Ellenberger C Jr. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981;21(8-9 Suppl):413S-416S.
16. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46(5):1306-10.
17. Simpson DM. Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve Suppl 1997;6:S169-75.
18. Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78(2):226-32.
19. Van Schaeybroeck P, Nuttin B, Lagae L, Schrijvers E, Borghgraef C, Feys P. Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery 2000;46(3):603-9.
20. Chambers HG: The surgical treatment of spasticity. Muscle Nerve Suppl 1997;6:S121-8.